Paolo Tarantino: Interesting sub analysis from the SENOMAC trial
Paolo Tarantino shared on X about a recent paper by Jana de Boniface et al. titled “Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial” published in the Lancet Oncology.
Authors: Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner, Yvette Andersson, Leif Bergkvist et al.
“55yo patient with grade 1, pT1c ER+ eBC and 2/2 positive sentinel LN at surgery. Should she undergo diagnostic ALND for deciding about adjuvant abema?
Interesting sub analysis from the SENOMAC trial published on The Lancet Oncology:
‘To avoid one invasive disease-free survival event at 5 years with adjuvant abemaciclib, cALND would need to be performed in 104 patients, and would result in nine patients having severe or very severe impairment of physical arm function 1 year after surgery.’ ”
Source: Paolo Tarantino/X